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Abstract 
A 64-year-old male patient was diagnosed with 3 consecutive non-small cell lung 
carcinomas (NSCLC). In the current study, we applied whole-genome gene expression 
analysis to control, primary and locally recurrent cancer, and supposed metastasis 
samples of a single patient. According to our knowledge, there are no published papers 
describing the gene expression profiles of a single patient’s squamous cell lung cancers. 
As the histology and differentiation grade of the primary cancer and the supposed 
metastasis differed minimally, but local recurrence was poorly differentiated, molecular 
profiling of the samples was carried out in order to confirm or reject the hypothesis of 
second primary cancer. Principal component analysis of the gene expression data 
revealed distinction of the local recurrence. Gene ontology analysis showed no 
molecular characteristics of metastasis in the supposed metastasis. Gene expression 
analysis is valuable and can be supportive in decision-making of diagnostically 
complicated cancer cases.  
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Case Report 
Clinical Data and Histology 
A 64-year-old male patient with a smoking history of 46 pack-years was diagnosed with peripheral 
tumour of the left upper lobe of the lung and underwent typical left upper lobectomy. As the upper lobe 
had near the primary tumour slight adhesions to the sixth segment, the upper lobe was resected 
anatomically and from the lower lobe atypically as one specimen. An Ethicon linear cutter was used for 
resection. Resection lines were macroscopically and microscopically cancer free and squamocellular 
cancer G2, in some areas G3 (fig. 1) was diagnosed histologically. TNM (tumour, node, metastasis) 
diagnosis after the specimen and resection line inspection was pT2N0M0R0 G2 stage IB. 
34 months later, on the sixth postoperative visit, a recurrent tumour of the left lung was diagnosed 
radiologically (CT scan). After removal of the cancer, the previous resection line in the middle of the 
tumour (fig. 1A2 arrow) could be seen, which clearly indicates local recurrence. Pleural invasion was 
present in the apical part of the removed parietal pleura. The recurrence had anaplastic cancer features 
with a very low differentiation grade (G4; fig. 1B2) and differed from the primary tumour mainly in its 
lack of tissue pattern and in immunohistochemical features (CK5/6 negative). Radiation therapy with 50 
Gy was administered to the pleural contact site. Polychemotherapy with cisplatin, etoposide and 
Vepesid was applied after the second surgical treatment. 
15 months after the second operation, a metastasis-like tumour of the right upper lobe was 
diagnosed radiologically (fig. 1A3). Squamocellular cancer G2 with keratinization in some areas was 
histologically confirmed (fig. 1B3). 
Tumour histology and stage were estimated according to the WHO/IASLC Histological 
Classification of Lung and Pleural Tumours [1] and TNM staging according to the UICC (International 
Union Against Cancer) classifications, respectively [2]. Control samples for the gene expression analysis 
were obtained from the same cancer patient at a site distant from the tumour and were approved as 
control samples by the pathologist. Histological evaluation was carried out on formalin-fixed, paraffin-
embedded tumour specimens. 
Analysis of Gene Expression and Ontology 
Postsurgical tissue specimens for gene expression analysis were immediately cut to an appropriate 
size and submerged in RNAlater (Ambion, Catalog No. AM7021) to inhibit RNA degradation. The 
samples were stored at –80°C until further processing. Total cellular RNA from tissue specimens of 50 
mg was extracted and purified using Ribopure Kit (Ambion, Catalog No. AM1924) according to the 
manufacturer’s instructions. For tissue disruption, the IKA Ultra-Turrax T8 homogenisator was used. 
RNA quantity and quality were assessed using the NanoDrop-1000 spectrophotometer and the Agilent 
Bioanalyzer lab-on-a-chip technology (Agilent RNA 6000 Nano Kit, catalog No. 5067-1511) 
respectively. The Illumina TotalPrep RNA Amplification Kit (Ambion, Catalog No. AMIL1971) was 
used for RNA amplification and labelling. Amplifications were carried out according to the 
manufacturer’s instructions using 300 ng of total RNA as a template. The Illumina BeadChip platform 
and the corresponding whole-genome HumanHT-12 v3 Expression BeadChip were used for the gene 
expression analysis. Experiments were carried out according to the manufacturer’s instructions. 
Illumina internal controls and BeadStudio software were used for data consistency and quality control 
of the hybridization raw data. Further data analysis was performed with R-software and Bioconductor 
package. Gene ontology (GO) enrichments were calculated using the g:Profiler web toolkit [3]. The GO 
analysis was performed with the gene lists representing at least 2-fold change of expression between the 
samples. 
As the gene expression difference between the primary control (obtained during the primary 
resection) and the recurrent cancer control (obtained during the supposed metastasis resection) samples 
was minimal, the further gene analyses were based on the comparison of samples of interest with the 
primary tumour control gene expression values. At least 2-fold change of expression between the 
samples was applied. The highest number of up- and downregulated genes (2,577 genes altogether) was 
identified between the locally recurrent cancer and the control sample (table 1). Surprisingly, the 
number of deregulated genes in the supposed metastasis sample (1,710) was substantially smaller than 
in primary cancer (2,095).  
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The GO analysis of 676 up- and 769 downregulated genes (at least 2-fold difference in expression 
was applied) between the supposed metastasis and primary cancer samples were performed in order to 
uncover the biological processes hindered within. 
As a result of the analysis, the biological processes associated with system and organ development, 
adhesion, oxidative stress, homeostasis as well as ossification came forth in the supposed metastasis 
sample. The known biological hallmarks of metastasis-associated processes like dedifferentiation, 
extensive metabolism, DNA synthesis and inflammation were not noted. GO analysis of genes 
downregulated in supposed metastasis revealed deactivation of processes like cellular localization, 
cytoskeleton and organelle organization, glucose catabolism and locomotion indicative of the more 
active nature of primary cancer compared with metastasis. 
Altogether these gene expression-based GO analyses did not support the hypothesis of metastasis. 
The molecular phenotype of the supposed metastasis was only minimally different from the primary 
cancer sample and the GO analysis revealed no activation of processes like matrix remodelling, 
metastasis, dedifferentiation, mitosis, etc., which are characteristic of metastatic cancers. Therefore, the 
evolvement of new primary cancer instead of metastasis is more probable. 
Correlations and Principal Component Analysis 
To visualize the gene expression data, a correlation heatmap (fig. 2) and principal component 
analysis (PCA) were performed (fig. 3). The correlation analysis as well as PCA revealed similar 
behaviour of the genes of the primary tumour control and the supposed metastasis control samples 
although there were 2 chemotherapy treatments between the sample collections. This indicates relatively 
minor changes in the gene expression profiles of histologically normal lung tissues collected prior to and 
after chemotherapy treatment. In the PC1/PC2 analysis, the recurrent cancer samples were most distant 
from controls and the supposed metastasis sample located in the middle section. Interestingly, the 
difference that can be measured as distance in the PCA between the control and the supposed metastasis 
samples is significantly smaller than distances between the control and the primary cancer samples as 
well as between the control samples and the recurrent cancer sample. Thus, according to the molecular 
profiles, one could suggest to reevaluate the status of the metastasis to a second primary cancer that 
should also be less aggressive than a primary and locally revived one. 
The results of PC2/PC3 analysis show that the supposed metastasis sample has the most distinct 
pattern. 
Discussion 
Approximately 7% of all cancer patients experience a new primary cancer later in life 
[4]. In the current case we have analysed and compared the histology and whole-genome 
mRNA expression levels within primary, recurrent and supposed metastatic lung cancer 
specimens. PCA and GO analysis were applied to reveal the molecular variance and 
activities of the tissues. 
As the histological patterns, clinical manifestation and performance of the patient were 
unexpected, the strong clinical suggestion of second primary disease instead of metastasis 
emerged. Supposed metastases and primary tumour had relatively similar histological 
differentiation. Clinically, the supposed metastasis had no common histological signs of 
previous chemotherapy like vacuolization, increased amount of apoptotic cells or 
inflammatory infiltration but had clear upregulation of genes as a response to a chemical 
stimulus which can be explained with previous chemotherapy (see online suppl. table 1, 
www.karger.com/doi/10.1159/000318010). The fact that supposed metastasis followed by 
chemotherapy was more similar to the primary tumour makes second primary cancer 
more likely. 
As a result of PCA of gene expression data, a clear distinction of recurrent cancer was 
seen, whereas similarities between supposed metastases and the primary tumour were  
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noted. The recurrence sample was histologically classified as undifferentiated and the 
clear distinction was also seen in PCA. In comparison of primary tumour and local 
recurrence samples, upregulation of processes like neural development, axonogenesis, 
neural degeneration processes and different developmental processes was seen in the 
recurrence sample (online suppl. table 1). The difference between the primary tumour 
and local recurrence could be explained by micrometastasis and the cancer stem cell 
phenomenon [5]. 
In the current case, we have shown the correlation of gene expression-based analysis 
with the histology of different control and cancer samples of one patient. The gene 
expression profiles supported the hypothesis of second primary squamous cell cancer of 
the lung. For 1 year and 10 months, since the third operation, the patient has had a good 
performance and recurrence-free life as controlled by CT scan, which is uncommon in 
everyday practice. Survival data support the second primary cancer hypothesis. The 
exclusion of the metastasis possibility is crucial in choosing the optimal treatment strategy 
and also results in a better prognosis of the patient. 
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Table 1. The up- and downregulated genes between different samples analysed 
 Primary 
cancer 
Recurrent 
cancer 
Supposed 
metastasis 
Primary
control 
Primary cancer    Ĺ 1,079  Ĺ 676  Ĺ 951 
Recurrent cancer  Ļ 1,026    Ĺ 1,109  Ĺ 1,274 
Supposed metastasis  Ļ 769  Ļ 951    Ĺ 822 
Primary control  Ļ 1,144  Ļ 1,303  Ļ 888   
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Fig. 1. Preoperative CT scans and histological staining of the resected tumours (HE, ×100). 
 
 
 
Fig. 2. Correlation heatmap representing the behaviour of gene expression changes between the 
samples. P = Primary cancer; R = recurrent cancer; M = supposed metastasis; CP = control sample 
obtained during the primary resection; CM = control sample obtained during the metastasis resection. 
The intensity of the red colour represents the positive gene expression correlation between the samples 
and the intensity of blue represents the discorrelation of the gene expression. 
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Fig. 3. PCA of primary and recurrent cancer, supposed metastasis, and control samples of primary 
cancer and of supposed metastasis gene expression data. There were replicate array data available for all 
except the supposed metastasis sample. R = Recurrent cancer; M = supposed metastasis; CM = control 
sample obtained during the supposed metastasis resection; P = primary cancer; CP = control sample 
obtained during the primary resection. 
 
  
Case Rep Oncol 2010;3:255–261 
DOI: 10.1159/000318010 
Published online: July 21, 2010  © 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
261
References 
1 Brambilla E, et al: The new World Health Organization classification of lung 
tumours. Eur Respir J 2001;18:1059–1068. 
2 Mountain CF: The international system for staging lung cancer. Semin Surg 
Oncol 2000;18:106–115. 
3 Reimand J, et al: g:Profiler – a web-based toolset for functional profiling of gene 
lists from large-scale experiments. Nucleic Acids Res 2007;35(Web Server 
issue):W193–W200. 
4 Engeland A, et al: Use of multiple primary cancers to indicate associations 
between smoking and cancer incidence: an analysis of 500,000 cancer cases 
diagnosed in Norway during 1953–93. Int J Cancer 1997;70:401–407. 
5 Eramo A, Haas TL, De Maria R: Lung cancer stem cells: tools and targets to fight 
lung cancer. Oncogene 2001, E-pub ahead of print. 
 
 
Tõnu Vooder and Kristjan Välk contributed equally to this work and share the first authorship. 